Skip to main content
SpringerLink
Log in

Shenfu Injection (参附注射液) suppresses inflammation by targeting haptoglobin and pentraxin 3 in rats with chronic ischemic heart failure

  • Original Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective

To investigate the regulatory effects of Shenfu Injection (SFI, 参附注射液) on hemodynamic parameters and serum proteins in rats with post-infarction chronic heart failure (CHF).

Methods

Forty-five healthy Wistar rats were randomized into three groups: sham, heart failure (model) and SFI group. The CHF was induced by left coronary artery ligation. Seven days after the surgical operation, animals in the sham group and the model group received saline (6.2 mL/kg/d), while animals in the SFI group received SFI (6.2 mL/kg d) intraperitoneally. Four weeks later, cardiac hemodynamic parameters were measured via the carotid route. The expression of serum proteins was analyzed by two-dimensional electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometer (MALDI-TOF MS).

Results

Recording of hemodynamic parameters showed that left ventricular systolic pressure (LVSP), maximum rate of left ventricular pressure (+dp/dtmax) rise, and maximum rate of left ventricular pressure (−dp/dtmax) decrease, while the left ventricular end diastolic pressure (LVEDP) rose in the model group compared to those in the sham group (P <0.05). The results of the MALDI-TOF MS indicated that haptoglobin (HP), pentraxin 3 (PTX3) and alpha-1-antitrypsin were up-regulated, while serum albumin and 40S ribosomal protein were down-regulated in the model group (P <0.05). Compared with the model group, LVSP, +dp/dtmax and −dp/dtmax were higher, while LVEDP was lower in the SFI group (P<0.05). Expression levels of HP and PTX3 were lower than in the model group (P<0.05).

Conclusion

SFI could improve hemodynamic function and decrease inflammatory reactions in the pathophysiology of CHF. The serum proteins HP and PTX3 could be potential biomarkers for chronic ischemic heart failure, and they could also be the serum protein targets of SFI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:e1–e82.

    Article  PubMed  Google Scholar 

  2. Niebauer J. Effects of exercise training on inflammatory markers in patients with heart failure. Heart Fail Rev 2008;13:39–49.

    Article  CAS  PubMed  Google Scholar 

  3. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 2005;95(11A):3C–8C.

    Article  CAS  PubMed  Google Scholar 

  4. Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet 2011;378:704–712.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Aukrust P, Gullestad L, Ueland T, Damas JK, Yndestad A. Inflammatory and anti-inflammatory cytokines in chronic heart failure: potential therapeutic implications. Ann Med 2005;37:74–85.

    Article  CAS  PubMed  Google Scholar 

  6. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 2002;91:988–998.

    Article  CAS  PubMed  Google Scholar 

  7. Wu Y, Xia ZY, Meng QT, Zhu J, Lei S, Xu J, et al. Shen-Fu injection preconditioning inhibits myocardial ischemiareperfusion injury in diabetic rats: activation of eNOS via the PI3K/Akt pathway. J Biomed Biotechnol 2011;2011:384627.

    PubMed Central  PubMed  Google Scholar 

  8. Wang YL, Wang CY, Zhang BJ, Zhang ZZ. Shenfu injection suppresses apoptosis by regulation of Bcl-2 and caspase-3 during hypoxia/reoxygenation in neonatal rat cardiomyocytes in vitro. Mol Biol Rep 2009;36:365–370.

    Article  CAS  PubMed  Google Scholar 

  9. Zheng CD, Min S. Cardioprotection of Shenfu Injection against myocardial ischemia/reperfusion injury in open heart surgery. Chin J Integr Med 2008;14:10–16.

    Article  PubMed  Google Scholar 

  10. Zhang BJ, Wang YL, Wang CY. Effect of Shenfu Injection on nuclear factor-kappaB during myocardial ischemia/reperfusion injury in rats. Chin J Traumatol (Chin) 2005;8:200–204.

    Google Scholar 

  11. Cao J, Zheng CD, Zhang GX, Zhang YJ, Min S. Protective effect of Shenfu Injection on myocardial mitochondria injured by ischemia-reperfusion in rabbits. Chin Med J 2005;118:505–507.

    CAS  PubMed  Google Scholar 

  12. Ji XF, Yang L, Zhang MY, Li CS, Wang S, Cong LH. Shen-Fu Injection attenuates post-resuscitation myocardial dysfunction in a porcine model of cardiac arrest. Shock 2011;35:530–536.

    Article  PubMed  Google Scholar 

  13. Luo J, Min S, Wei K, Cao J. Ion channel mechanism and ingredient bases of Shenfu Decoction’s cardiac electrophysiological effects. J Ethnopharmacol 2008;117:439–445.

    Article  PubMed  Google Scholar 

  14. Luo XY, Zhang FR, He RM. Efficacy of Shenfu Injection as adjuvant therapy in treating patients of ischemic cardiomyopathy with heart insufficiency. Chin J Integr Tradit West Med (Chin) 2009;29:685–687.

    Google Scholar 

  15. Hu YH, Wu HQ, Qi X. Influence of Shenfu Injection on heart function and bone marrow stem cell mobilization in patients with chronic heart failure of coronary heart disease. Chin J Integr Tradit West Med (Chin) 2009;29:309–312.

    Google Scholar 

  16. Wang J, Qiao LF, Yang GT. Role of Shenfu Injection in rats with systemic inflammatory response syndrome. Chin J Integr Med 2008;14:51–55.

    Article  PubMed  Google Scholar 

  17. Ke DZ, Chen QW, Li CL, Li GQ. Cytokines mechanism of Shenfu Injection in treatment of cardiogenic shock in canine. China J Chin Mater Med (Chin) 2007;32:2273–2277.

    Google Scholar 

  18. Maki T, Nasa Y, Tanonaka K, Takahashi M, Takeo S. Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation. J Pharmacol Exp Ther 2003;305:97–105.

    Article  CAS  PubMed  Google Scholar 

  19. Wu HJ, Zhang YL. The effects of Shenfu Injection on apoptosis related factors in rat model of heart failure. Chin J Integr Med Cardio/Cerebrovasc Dis (Chin) 2009;7:926–928.

    Google Scholar 

  20. Kinugawa S, Tsutsui H, Hayashidani S, Ide T, Suematsu N, Satoh S, et al. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 2000;87:392–398.

    Article  CAS  PubMed  Google Scholar 

  21. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248–254.

    Article  CAS  PubMed  Google Scholar 

  22. Kwak JY, Ma TZ, Yoo MJ, Choi BH, Kim HG, Kim SR, et al. The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia. Exp Hematol 2004;32:836–842.

    Article  CAS  PubMed  Google Scholar 

  23. Shevchenko A, Chernushevic I, Wilm M, Mann M. “De novo” sequencing of peptides recovered from in-gel digested proteins by nanoelectrospray tandem mass spectrometry. Mol Biotechnol 2002;20:107–118.

    Article  CAS  PubMed  Google Scholar 

  24. Ying W, Zhang K, Qian X, Xie L, Wang J, Xiang X, et al. Proteome analysis on an early transformed human bronchial epithelial cell line, BEP2D, after alpha-particle irradiation. Proteomics 2003;3:64–72.

    Article  CAS  PubMed  Google Scholar 

  25. Lim H, Eng J, Yates JR, 3rd, Tollaksen SL, Giometti CS, Holden JF, et al. Identification of 2D-gel proteins: a comparison of MALDI/TOF peptide mass mapping to mu LC-ESI tandem mass spectrometry. J Am Soc Mass Spectrom 2003;14:957–970.

    Article  CAS  PubMed  Google Scholar 

  26. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, et al. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008;155:75–81.

    Article  CAS  PubMed  Google Scholar 

  27. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002;22:e10–e14.

    Article  PubMed  Google Scholar 

  28. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004;110:2349–2354.

    Article  CAS  PubMed  Google Scholar 

  29. Kotooka N, Inoue T, Aoki S, Anan M, Komoda H, Node K. Prognostic value of pentraxin 3 in patients with chronic heart failure. Int J Cardiol 2008;130:9–22.

    Article  Google Scholar 

  30. Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K, et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 2011;57:861–869.

    Article  CAS  PubMed  Google Scholar 

  31. Kaess BM, Vasan RS. Heart failure: pentraxin 3—a marker of diastolic dysfunction and HF? Nat Rev Cardiol 2011;8:246–248.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Ishino M, Takeishi Y, Niizeki T, Watanabe T, Nitobe J, Miyamoto T, et al. Risk stratification of chronic heart failure patients by multiple biomarkers: implications of BNP, H-FABP, and PTX3. Circ J 2008;72:1800–1805.

    Article  CAS  PubMed  Google Scholar 

  33. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009;11:119–129.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Quaye IK. Haptoglobin, inflammation and disease. Trans R Soc Trop Med Hyg 2008;102:735–742.

    Article  CAS  PubMed  Google Scholar 

  35. Fouad FM, Mamer O, Sauriol F, Khayyal M, Lesimple A, Ruhenstroth-Bauer G. Cardiac heart disease in the era of sucrose polyester, Helicobacter pylori and Chlamydia pneumoniae. Med Hypotheses 2004;62:257–267.

    Article  CAS  PubMed  Google Scholar 

  36. Suleiman M, Aronson D, Asleh R, Kapeliovich MR, Roguin A, Meisel SR, et al. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 2005;54:2802–2806.

    Article  CAS  PubMed  Google Scholar 

  37. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Haptoglobin and risk of myocardial infarction, stroke, and congestive heart failure in 342,125 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Ann Med 2009;41:522–532.

    Article  CAS  PubMed  Google Scholar 

  38. Wang Y, Zhou Y, Meng L, Lu X, Ou N, Li X. Inflammatory mediators in Chinese patients with congestive heart failure. J Clin Pharmacol 2009;49:591–599.

    Article  CAS  PubMed  Google Scholar 

  39. van Empel VP, Bertrand AT, Hofstra L, Crijns HJ, Doevendans PA, De Windt LJ. Myocyte apoptosis in heart failure. Cardiovasc Res 2005;67:21–29.

    Article  PubMed  Google Scholar 

  40. Song WT, Cheng FF, Xu, L, Lin CR, Liu JX. Chinese medicine Shenfu Injection for heart failure: a systematic review and meta-analysis. Evid Based Complement Alternat Med 2012;2012:713149.

    Google Scholar 

  41. Dasgupta A, Reyes MA. Effect of Brazilian, Indian, Siberian, Asian, and North American ginseng on serum digoxin measurement by immunoassays and binding of digoxin-like immunoreactive components of ginseng with Fab fragment of antidigoxin antibody (Digibind). Am J Clin Pathol 2005;124:229–336.

    Article  CAS  PubMed  Google Scholar 

  42. Liao WI, Lin YY, Chu SJ, Hsu CW, Tsai SH. Bradyarrhythmia caused by ginseng in a patient with chronic kidney disease. Am J Emerg Med 2010;28:538.e5–538.e6.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Beijing, 100039, China

    Si-dao Zheng  (郑思道), Hong-jin Wu  (吴红金), Shao-ping Yu  (余少平), Jian-xun Ren, Wei-wei Duo  (多韦唯) & Yu-na Liu  (刘宇娜)

  2. Beijing Institute of Radiation Medicine, Beijing, 100850, China

    Zeng-chun Ma  (马增春), Yue Gao  (高 月) & Sheng-qi Wang  (王升启)

Authors
  1. Si-dao Zheng  (郑思道)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hong-jin Wu  (吴红金)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shao-ping Yu  (余少平)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jian-xun Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wei-wei Duo  (多韦唯)
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zeng-chun Ma  (马增春)
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yue Gao  (高 月)
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sheng-qi Wang  (王升启)
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yu-na Liu  (刘宇娜)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hong-jin Wu  (吴红金).

Additional information

Supported by the Science and Technology Fund of the Beijing Bureau of Traditional Chinese Medicine (No. JJ2001-37) and the National Nature Science Foundation of China (No. 81173367)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zheng, Sd., Wu, Hj., Yu, Sp. et al. Shenfu Injection (参附注射液) suppresses inflammation by targeting haptoglobin and pentraxin 3 in rats with chronic ischemic heart failure. Chin. J. Integr. Med. 21, 22–28 (2015). https://doi.org/10.1007/s11655-013-1440-8

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-013-1440-8

Keywords

Search

Navigation